Login to Your Account



Other News To Note


Wednesday, May 2, 2012
• ImmuVen Inc., of Champaign, Ill., said it received a Phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute of Allergy and Infectious Diseases for continuing development of IMV0123, its therapeutic program against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription